Clinical trials: Malignant Tumors
Cervical Cancer, Endometrial Cancer
HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China
This study aims to retrospectively analyze the HER2 expression of gynecological malignant tumors in Chongqing by immunohistochemical detection, and explore the correlation between HER2 level, therapy response and prognosis based…
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Cancer, HER2 Expression
- Trial name
- NCT06238284
- Testing
- no intervention
- Volunteers
- 300 people
- Sponsor
- Chongqing University Cancer Hospital
Glioblastoma (GBM)
Sonodynamic-Chemoradiotherapy Integration in Glioblastoma
This Phase II trial tests if sonodynamic therapy (SDT)-a non-invasive treatment using ultrasound to activate a cancer-killing drug-improves outcomes for newly diagnosed glioblastoma patients.
- Trial name
- NCT07130149
- Testing
- Sonodynamic Therapy (SDT), Standard Treatment
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Yingjuan Zheng
Neurofibromatosis 1 and 2 (NF1 and NF2)
A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)
Patients with clinically confirmed neurofibromatosis type 1 (NF1) or neurofibromatosis type 2 (NF2) or a known neurofibromatosis (NF) mutation aged 5 years and above will be eligible to participate and will be recruited from the…
- Trial name
- NCT03672838
- Testing
- hand-held dynamometer
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- NYU Langone Health
Recurrent or Metastatic, Advanced Solid Tumors
Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors
A Phase Ia Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of IMB071703 Injection in Subjects with Recurrent or Metastatic，Advanced Solid Tumors
- Trial name
- NCT06292858
- Testing
- IMB071703 injection
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Beijng Immunoah Pharma Tech Co., Ltd.
Skin Cancer Excision Site, Basal Cell Carcinoma
Impact of Dysport on PMFF Donor Scar
The purpose of this research study is to investigate the effect of pre-operative injections of Dysport (Abobotulinumtoxin-A, commonly known as "Botox") on the cosmetic appearance of and overall satisfaction with study…
- Conditions
- Skin Cancer Excision Site, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
- Trial name
- NCT07720726
- Testing
- Abobotulinumtoxin-A, Control- Saline injection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt University Medical Center
Neoplasms, Malignancies
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
The purpose of this study is to find the safest dose level of an approved drug, carfilzomib, in solid tumors when given over a different period of time than normally used.
- Trial name
- NCT02257476
- Testing
- Carfilzomib, Dexamethasone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Emory University
Medulloblastoma
Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma
Survivors of pediatric medulloblastoma (MB) are at-risk for neurocognitive and social deficits, including specific skills such as facial affect recognition which is the ability to recognize the emotional expressions of another…
- Trial name
- NCT02747576
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Solid Tumor
An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors
This is an open-label, non-randomized, single-center, dose-escalation study in patients with advanced solid tumors. Six dose levels (100, 200, 400, 600, 800, and 1000 mg/day) are planned for the study.
- Trial name
- NCT00657176
- Testing
- OPB-31121
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Merkel Cell Carcinoma
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines
Merkel cell carcinoma (MCC) is a rare aggressive skin carcinoma. Approximately 80% of MCC are related to the Merkel Cell Polyomavirus (MCPyV). Although rates of relapse are high, the follow-up strategy lacks consensus.
- Trial name
- SUMMERTIME (NCT04705389)
- Testing
- Samples
- Where
- 10 sites in Austria, Finland and 8 more
- Volunteers
- 35 people
- Sponsor
- University Hospital, Tours
Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
RVU120 Rollover Study
This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when…
- Conditions
- Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- Trial name
- ROVER-01 (NCT06987058)
- Testing
- RVU120, Ruxolitinib
- Where
- 7 sites in France, Poland
- Volunteers
- 14 people
- Sponsor
- Ryvu Therapeutics SA
Metastatic Solid Tumor
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a two-part, open-label phase 1 study to evaluate safety and preliminary efficacy of M-CENK Suspension for Infusion, Cryopreserved, and N-803 for subcutaneous administration in subjects with locally advanced or metastatic…
- Trial name
- NCT04898543
- Testing
- M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B), Apheresis collection of MNCs (part A)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunityBio, Inc.
Glioblastoma
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
The goal of this clinical research study is to learn if cilengitide given in combination with bevacizumab can help to control glioblastoma. The safety of this drug combination will also be studied.
- Trial name
- NCT01782976
- Testing
- Cilengitide, Bevacizumab, Questionnaire
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Renal Cell Carcinoma, Metastatic Malignant Melanoma
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.
- Trial name
- NCT00625768
- Testing
- AS1409
- Where
- 4 sites in New Zealand, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Antisoma Research
Unspecified Adult Solid Tumor, Protocol Specific
Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of lurtotecan liposome in treating patients who have…
- Trial name
- NCT00003891
- Testing
- lurtotecan liposome
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- NCIC Clinical Trials Group
Glioblastoma (GBM)
Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic
The goal of this sub-study of the RESTORE trial is to identify biomarkers associated with tumor hypoxia, identify biomarkers that differentiate pseudoprogression from true progression, and correlate biomarkers with clinical…
- Trial name
- RESTORE LB (NCT07417774)
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- NuvOx LLC
Melanoma
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
This is a Phase II, open-label, randomized, multi-center study to assess the efficacy and safety of IBI363 monotherapy compared to Pembrolizumab in the treatment of patients with unresectable locally advanced or metastatic…
- Trial name
- NCT06797297
- Testing
- IBI363, Pembrolizumab
- Where
- 31 sites in China
- Volunteers
- 180 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Stage IV Melanoma, Stage III Melanoma
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
This phase 2 trial will investigate the efficacy and safety of trametinib and dabrafenib in patients with advanced BRAF V600 (v-Raf murine sarcoma viral oncogene homolog B) wild-type melanoma (stratified according to BRAF V600…
- Trial name
- TraMel-WT (NCT04059224)
- Testing
- Trametinib, Dabrafenib
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- Universitair Ziekenhuis Brussel
Gastrointestinal Stromal Tumors
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be studied in these patients.
- Trial name
- NCT01396148
- Testing
- sunitinib malate dose escalation, sunitinib malate
- Where
- 9 sites in United States, Czechia and 1 more
- Volunteers
- 6 people
- Sponsor
- Pfizer
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
This phase I/II trial studies the side effects and best dose of gefitinib when given together with radiation therapy and to see how well it works in treating patients with glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00052208
- Testing
- gefitinib, radiation therapy, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)